In the last trading session, 1.08 million Edgewise Therapeutics Inc (NASDAQ:EWTX) shares changed hands as the company’s beta touched 0.23. With the company’s per share price at $25.08 changed hands at $0.07 or 0.28% during last session, the market valuation stood at $2.37B. EWTX’s last price was a discount, traded about -51.99% off its 52-week high of $38.12. The share price had its 52-week low at $14.90, which suggests the last value was 40.59% up since then.
Analysts gave the Edgewise Therapeutics Inc (EWTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended EWTX as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Edgewise Therapeutics Inc’s EPS for the current quarter is expected to be -0.42.
Edgewise Therapeutics Inc (NASDAQ:EWTX) trade information
Instantly EWTX was in green as seen at the end of in last trading. With action -4.02%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -6.07%, with the 5-day performance at -4.02% in the red. However, in the 30-day time frame, Edgewise Therapeutics Inc (NASDAQ:EWTX) is -11.38% down.
The consensus price target for the stock as assigned by Wall Street analysts is 46, meaning bulls need an upside of 45.48% from its current market value. According to analyst projections, EWTX’s forecast low is 42 with 51 as the target high. To hit the forecast high, the stock’s price needs a -103.35% plunge from its current level, while the stock would need to soar -67.46% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -68.02%. The 2025 estimates are for Edgewise Therapeutics Inc earnings to increase by 5.75%, but the outlook for the next 5-year period is at -12.14% per year.
EWTX Dividends
Edgewise Therapeutics Inc is expected to release its next quarterly earnings report in March.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 9.5269% or 8.91 million shares worth $160.45 million as of 2024-06-30.
